Interim Management Statement

RNS Number : 4587H
Hikma Pharmaceuticals Plc
05 November 2008

London, 5 November 2008 - Hikma Pharmaceuticals PLC ("Hikma")(LSE:HIK)(DIFX:HIK), the fast growing multinational pharmaceutical group
focused on developing, manufacturing and marketing a broad range of generic and in-licensed pharmaceutical products, is today updating the
market on its current trading and financial position relating to the period from 1 July 2008 to date as required by the UK Listing
Authority's Disclosure and Transparency Rules.

Sales continued to grow steadily in the period and in the nine months to 30 September 2008 Group sales grew by approximately 32%. Since
the end of September, the Branded and Injectables businesses have continued to drive sales growth in the Group and we are confident of
delivering Group sales growth above 30% for the full year.

We continued to see excellent growth in our Branded business during the period, driven by favourable market demographics across the MENA
region. Organic sales growth remained strong, with further growth coming from the integration of APM and Hikma Egypt, which continued to
perform extremely well. We remain confident that we will deliver Branded revenue growth of approximately 60% for the full year. As in the
first half, Branded operating margins for the full year will reflect the cost of the additional investment required to support the strong
growth seen in this segment of the business.

Our global Injectables business continued to perform well in the MENA region during the period, benefiting from strong demand for our
products. Sales in our US injectables business also progressed in line with our expectations. Sales growth in our European markets was
lower than expected, reflecting lower volumes and increased pricing pressure, and we expect this to continue through the end of the year.

In our Generics business, where difficult trading conditions in the US led to an operating loss for the first half of the year, efforts
to improve operating performance were ongoing during the period. As anticipated at the time of our interim results, these efforts have
begun to have an effect, and we remain on track to reduce operating losses in the second half as previously reported to the market.

Our current net debt position is largely unchanged since the end of June. We expect to continue to benefit from the diversity of our
debt financing, which is spread across multiple banks and geographies and which limits refinancing risk.

We will announce our preliminary results for the twelve months to 31 December 2008 on 17 March 2009.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC
Said Darwazah, Chief Executive Officer
Bassam Kanaan, Chief Financial Officer
Susan Ringdal, Investor Relations Director Tel: +44 (0)20 7399 2760

Brunswick Group
Jon Coles / Justine McIlroy Tel: +44 (0)20 7404 5959

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both
branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where
it is a market leader and sells across 17 countries, the United States and Europe. In 2007, the Group achieved revenues of $449 million and
profit attributable to shareholders was $63 million. For news and other information, please visit www.hikma.com.

This information is provided by RNS
The company news service from the London Stock Exchange

END

IMSUUGRWGUPRGBC

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024